Intangible Assets

12 Months Ended

Dec. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

7. Intangible Assets

The net carrying value of the identifiable intangible assets from all acquisitions within continuing operations as of December 31, 2023 and December 31, 2022 are as follows:

			As of December 31, 2023			As of December 31, 2022
	Life		Carrying			Carrying
	(Years)		Amount			Amount
Asuragen acquisition:
Thyroid		9	$	8,519		$	8,519
RedPath acquisition:
Pancreas test		7		16,141			16,141
Barrett’s test		9		6,682			6,682
CLIA Lab		2.3		609			609
Total			$	31,951		$	31,951
Accumulated Amortization				(31,951	)		(31,090	)
Net Carrying Value			$	-		$	861

Amortization expense from continuing operations was approximately $0.9 million and $1.3 million for the years ended December 31, 2023 and 2022, respectively. The Company’s identifiable intangible assets were fully amortized as of December 31, 2023.